🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Sean J. Belouin

Substance Abuse and Mental Health Services Administration

ORCID: 0000-0002-6231-8992

Also affiliated with Office of the Assistant Secretary for Health, United States Public Health Service, Office of Science, Office of the Secretary of Health and Human Services, National Institutes of Health Clinical Center

PsychologyChemistryNeuroscienceAgricultural and Biological SciencesPharmacology, Toxicology and Pharmaceutics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 5%percentile
0.475Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

National Institutes of Health psilocybin research speaker series: State of the science, regulatory and policy landscape, research gaps, and opportunities

Neuropharmacology(2023)10.1016/j.neuropharm.2023.109467
Top 40%
0.475DataRank
Top 40%11 citations

Ann M. Berger, David Shurtleff, Farah Zia, Sean J. Belouin, Dan Xi

Papers

Driven by 4 papers — median percentile 60. Top paper: “National Institutes of Health psilocybin research speaker series: State of the science, regulatory and policy landscape, research gaps, and opportunities”.

National Institutes of Health psilocybin research speaker series: State of the science, regulatory and policy landscape, research gaps, and opportunities

Neuropharmacology(2023)10.1016/j.neuropharm.2023.109467
Top 40%
0.475DataRank
Top 40%11 citations

Ann M. Berger, David Shurtleff, Farah Zia, Sean J. Belouin, Dan Xi

Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines

Neuropharmacology(2022)10.1016/j.neuropharm.2022.109214
N/A
0DataRank · unranked
49 citations

Lynnette A. Averill, Jack E. Henningfield, Stephen N. Xenakis, Ingrid Donato, Charles S. Grob +5 more

Are psychedelic medicines the reset for chronic pain? Preliminary findings and research needs

Neuropharmacology(2023)10.1016/j.neuropharm.2023.109528
N/A
0DataRank · unranked
28 citations

Michael H. Baumann, Sean J. Belouin, Robert H. Dworkin, Majid H. Ghauri, Peter S. Hendricks +5 more

Dedication: Roland R. Griffiths (July 19, 1946–October 16, 2023)

Neuropharmacology(2024)10.1016/j.neuropharm.2024.109945
N/A
0DataRank · unranked
2 citations

Sean J. Belouin, Jack E. Henningfield